PBYI
PUMA BIOTECHNOLOGY, INC. · Healthcare · Market cap $506.9M
Insiders sold $1.1M net in the last 90 days ·5 sellers, 0 buyers· 5 of 5 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 17, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.1M
reported sales (SEC code S)
Unique Insiders
10
in the rolling window
Latest filing
Sep 17, 2026
WILSON TROY EDWARD
PUMA BIOTECHNOLOGY, INC. (PBYI) has 19 SEC Form 4 filings (28 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Sep 17, 2026.
Inside the rolling window, 10 insiders at PUMA BIOTECHNOLOGY, INC. reported no open-market purchases and 17 open-market sales totaling $2.1M. The most active filer is President and CEO AUERBACH ALAN H with 3 filings. Insiders have net sold $1.7M over the trailing 6 months. The most recent open-market filing is a sale of 5,000 shares by Director WILSON TROY EDWARD, dated Sep 14, 2026, worth $46K.
- Industry:Biotechnology
- CEO:Alan H. Auerbach
- Employees:179
- HQ:Los Angeles, CA, US
- IPO:2012-04-24
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Director | Sale | 5,000 | $46K | Sep 17 | +3.2% | SEC ↗ | |
Cesano AlessandraFirst filing | Director | Sale | 62,150 | $567K | Sep 17 | +3.2% | SEC ↗ |
AUERBACH ALAN HFirst in 6 months | President and CEO | Sale | 44,058 | $364K | Jul 9 | +24.3% | SEC ↗ |
HUNT DOUGLAS MFirst in 6 months | See Remarks | Sale | 8,460 | $70K | Jul 9 | +24.3% | SEC ↗ |
NOUGUES MAXIMO FFirst in 6 months | Chief Financial Officer | Sale | 9,386 | $78K | Jul 9 | +24.3% | SEC ↗ |
MOYES JAY MFirst in 4 months | Director | Sale | 22,000 | $159K | Jun 15 | +38.9% | SEC ↗ |
Stuglik Brian MFirst in 6 months | Director | Sale | 8,100 | $58K | Jun 15 | +38.9% | SEC ↗ |
Dorval AllisonFirst filing | Director | Sale | 11,610 | $84K | Jun 15 | +38.9% | SEC ↗ |
WILSON TROY EDWARDFirst in 9 months | Director | Sale | 10,800 | $78K | Jun 15 | +38.9% | SEC ↗ |
Senderowicz AdrianFirst filing | Director | Sale | 27,000 | $194K | Jun 15 | +38.9% | SEC ↗ |
HUNT DOUGLAS MFirst filing | See Remarks | Sale | 3,973 | $23K | Jan 8 | — | SEC ↗ |
HUNT DOUGLAS MFirst filing | See Remarks | Sale | 5,014 | $29K | Jan 8 | — | SEC ↗ |
AUERBACH ALAN HFirst filing | President and CEO | Sale | 16,938 | $99K | Jan 8 | — | SEC ↗ |
AUERBACH ALAN HFirst filing | President and CEO | Sale | 18,012 | $106K | Jan 8 | — | SEC ↗ |
NOUGUES MAXIMO FFirst filing | Chief Financial Officer | Sale | 4,540 | $27K | Jan 8 | — | SEC ↗ |
NOUGUES MAXIMO FFirst filing | Chief Financial Officer | Sale | 6,405 | $38K | Jan 8 | — | SEC ↗ |
MILLER MICHAEL PATRICKFirst filing | Director | Sale | 20,000 | $97K | Nov 13 | — | SEC ↗ |
Congress trading PBYI 2 all-time
- DRep. Donna ShalalaPurchase$1,001 - $15,0002019-01-23
- DRep. Donna ShalalaOther$1,001 - $15,0002019-05-15
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does PBYI have?
PUMA BIOTECHNOLOGY, INC. (PBYI) has 19 SEC Form 4 filings (28 transaction rows) in the rolling 365-day window, disclosed by 10 distinct insiders. Most recent filing: Sep 17, 2026.
When was the most recent SEC Form 4 filing for PBYI?
The most recent Form 4 filing for PBYI on Tracefour is dated Sep 17, 2026.
Who is the most active insider at PBYI?
The most active SEC Form 4 filer at PBYI in the rolling window is President and CEO AUERBACH ALAN H, with 3 filings.
What is the net insider flow at PBYI over the last 6 months?
Over the trailing 180 days, insiders at PBYI have net sold $1.7M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at PBYI in the current window?
Inside the rolling window, insiders at PBYI bought $0 and sold $2.1M based on SEC Form 4 filings.
Can I get alerts for PBYI insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at PUMA BIOTECHNOLOGY, INC. (PBYI). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
PUMA BIOTECHNOLOGY, INC. is in the Healthcare sector.